Malarone Pediatric Oral Tablet 62.5-25Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Malarone Pediatric: Oral tablet (62.5-25mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_3330.JPG
Malarone Pediatric Tab
GlaxoSmithKline Group of Companies
Pill Identification: GX CG7 
Drug Image file DrugItem_14656.JPG
Atovaquone/Proguanil Ped Tab
Glenmark Pharmaceuticals
Pill Identification: GX CG7 

What is this Medicine?

ATOVAQUONE; PROGUANIL (a TOE va kwone; pro GWAN il) is an antimalarial agent. It is used to prevent and to treat malaria infections.

In-Depth Information

Malarone Pediatric 62.5mg-25mg Tablet

NDC: 001730676
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Malaria Prophylaxis, Malaria

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Malarone Pediatric 62.5mg-25mg Tablet
Drug Image file DrugItem_3330.JPG
GlaxoSmithKline Group of Companies
Pill Identification: GX CG7 
Shape: round
Color: pink

Reported Side Effects for Malarone Pediatric 62.5mg-25mg Tablet

Upset Stomach Incidence:
<14.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Photosensitivity Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Pancytopenia Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Liver Failure Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Hallucinations Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Anaphylactoid Reactions Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Vomiting Incidence:
<13.0%*
Severity: MILD
Onset: EARLY
Inflamed Blood Vessels Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Convulsions Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Infection Incidence:
<8.0%*
Severity: MILD
Onset: DELAYED
Liver Infection Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Cholestasis Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Mouth Ulcers Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Stevens-Johnson Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Anemia Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Low White Blood Cells Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Angioedema Incidence:
<1.0%*
Severity: SEVERE
Onset: RAPID
Nervousness Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Depression Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Erythema Multiforme Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Loose Stools Incidence:
1.0-38.0%*
Severity: MILD
Onset: EARLY
Flu Incidence:
2.0-9.0%*
Severity: MILD
Onset: DELAYED
Inflamed Stomach Incidence:
2.0-3.0%*
Severity: MODERATE
Onset: DELAYED
Upset Stomach Incidence:
2.0-3.0%*
Severity: MILD
Onset: EARLY
Mouth Sores Incidence:
2.0-9.0%*
Severity: MODERATE
Onset: DELAYED
Stomach Pain Incidence:
2.0-33.0%*
Severity: MILD
Onset: EARLY
Itching Incidence:
3.0-6.0%*
Severity: MILD
Onset: RAPID
Back Pain Incidence:
4.0-8.0%*
Severity: MILD
Onset: DELAYED
Inability To Sleep Incidence:
4.0-5.0%*
Severity: MILD
Onset: EARLY
Cough Incidence:
4.0-10.0%*
Severity: MILD
Onset: DELAYED
Fever Incidence:
5.0-9.0%*
Severity: MILD
Onset: EARLY
Lightheadedness Incidence:
5.0-7.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
5.0%*
Severity: MILD
Onset: DELAYED
Muscle Pain Incidence:
7.0-12.0%*
Severity: MILD
Onset: EARLY
Weakness Incidence:
8.0%*
Severity: MILD
Onset: DELAYED
Headache Incidence:
10.0-22.0%*
Severity: MILD
Onset: EARLY
Elevated Hepatic Enzymes Incidence:
16.9-26.7%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Malarone Pediatric

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5